Related Experiment Videos
Practical suggestions in diagnosing metachromatic leukodystrophy in probands and in testing family members
A T Tylki-Szymańska1, B Czartoryska, A Lugowska
1The Children's Memorial Health Institute, Department of Metabolic Diseases, Warsaw, Poland.
Abstract:
Metachromatic leukodystrophy (MLD) is one of the most severe genetically determined demyelination diseases. It is caused by a deficit in the activity of sulfatide sulfatase. The diagnosis is made by demonstrating a deficiency of arylsulfatase A (ASA) activity in leukocytes or cultured skin fibroblasts. Diagnosis based only on the activity of ASA is complicated by the fact that there exists a condition of ASA pseudodeficiency (Pd). Due to the relatively high risk of the MLD/Pd and MLDPd/Pd genotypes among families of patients, it is possible to make an erroneous diagnosis on the basis of only ASA activity. Nonetheless, it seems necessary to develop a reliable and simple diagnostic procedure so as to enable diagnosis and genetic counseling for carriers. We present two diagnostic flow charts entailing determination of ASA activity, identification of the pseudodeficit mutation and detection of sulfatides in a 24-hour urine collection.
Insights
Metachromatic leukodystrophy (MLD) diagnosis is challenging due to arylsulfatase A (ASA) pseudodeficiency. New diagnostic flow charts combine ASA activity testing, mutation identification, and sulfatide detection for accurate MLD diagnosis and genetic counseling.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- Metachromatic leukodystrophy (MLD) is a severe genetic demyelination disorder.
- MLD results from deficient sulfatide sulfatase activity.
- Diagnosing MLD via arylsulfatase A (ASA) activity is complicated by ASA pseudodeficiency (Pd).
Purpose of the Study:
- To develop reliable and simple diagnostic procedures for Metachromatic Leukodystrophy.
- To aid in accurate diagnosis and genetic counseling for families at risk.
- To address diagnostic challenges posed by ASA pseudodeficiency.
Main Methods:
- Determination of arylsulfatase A (ASA) activity in patient samples.
- Identification of specific arylsulfatase A (ASA) pseudodeficiency mutations.
- Detection of sulfatides in 24-hour urine collections.
Main Results:
- Presented diagnostic flow charts integrate multiple testing methods.
- The proposed methods aim to differentiate true MLD from ASA pseudodeficiency.
- Enables more accurate genetic diagnosis and carrier screening.
Conclusions:
- Accurate diagnosis of MLD requires more than just ASA activity testing.
- Combining ASA activity, mutation analysis, and sulfatide detection improves diagnostic reliability.
- These flow charts facilitate precise diagnosis and informed genetic counseling for MLD and Pd.